

Subject Index Vol. 91–100

- Absorption; (92) 197; (99) 165
 Absorption enhancer; (95) 101; (95) 209; (99) 165
 Absorption promoter; (93) 91
 Acebutolol hydrochloride; (93) 13
 Acetaminophen; (93) 111; (96) 119
 Acetylsalicylic acid; (92) 151
 Acid-base interaction; (94) 223
 Acidity constant; (91) R1
 Acipimox; (95) 127
 ACNU; (99) 73
 Acquired immunodeficiency syndrome (AIDS); (95) 1
 Acrylic polymer; (100) 207
 Acryloyl-L-proline methyl ester; (95) 153
 Activation energy; (94) 189; (95) 143
 Acute toxicity; (98) 121
 Acyclovir; (99) 79
 Acylation; (93) 177
 Additive-polymer interaction; (94) 39
 Adherence; (99) 93
 Adhesion; (91) 227; (94) 223
 Adinazolam; (99) 311
 β -Adrenergic antagonist; (99) 303
 Adsorption; (99) 59
 Adsorption isotherm; (91) 227; (93) 221
 Adult human skin; (98) 93
 Aerosol; (93) 221; (95) 111; (97) 205; (98) 45; (99) R1; (100) 123
 Affinity constant; (95) 117
 Aging; (96) 5; (97) 119
 AIDS; (98) 45; (99) R1
 Albendazole absorption; (91) 105
 Alginate; (97) 183
 Alginate gel beads; (96) 139
 Alginate microsphere; (95) 77
 1-Alkylaminocarbonyl 5-fluorouracil; (93) 27; (93) 37
 1-Alkylcarbonyl-5-fluorouracil; (93) 37
 1-Alkylloxycarbonyl-5-fluorouracil; (93) 37
 Alleviator; (93) 1
 Aluminum hydroxide gel; (97) 141
 Alveolar echinococcosis; (100) 271
 Amethocaine phase-change system; (94) 75
 Amide bond hydrolysis; (92) 63
 Amiloride; (91) 195
 Amino acid; (99) 43
 Amino group determination; (96) 85
 Aminoquinoline; (100) 15
 Ammonium glycyrrhizinate; (94) 161
 Ampicillin; (97) 219; (99) 119
 Amylodextrin; (98) 219
 Analog; (92) 63
 Animal model; (100) 133
 Animal study; (95) 229
 Anisotropy; (95) 143
 Antibacterial activity; (98) 1
 Antibody; (98) 149
 Antifungal agent; (94) 11
 Anti-HIV drug; (95) 1
 Antimalarial; (100) 15
 Antimicrobial; (93) 131
 Antimicrobials; (93) 121
 Antioestrogen; (99) 59
 Antitack additive; (94) 39
 Antitumor activity; (98) 121
 Aprotinin; (95) 101
 APSAC; (93) 177
 Aqueous colloidal dispersion; (96) 129
 Aqueous film coating; (94) 39
 Aqueous solution; (98) 225
 Aqueous spray; (100) 241
 Aqueous stagnant layer; (91) 235
 9- β -D-Arabinofuranosyladenine; (95) 153
 Aromatic compound; (94) 81
 L-Asparaginase; (96) 67
 Assay; (94) 231
 Asthma therapy; (97) 47
 Atenolol; (95) 161
 Atomic charge; (94) 81
 Atropine sulfate; (93) 239
 Attenuated total reflectance; (91) 51
 Autoclaving; (92) 233
 3'-Azido-3'-deoxythymidine; (93) 75
 4'-Azidothymidine; (93) 75
 Azidothymidine; (96) 249
 Azobenzene polymer; (99) R5
 Azone; (91) 85; (98) 173
 Azo polymer; (97) 133
 Bacterial adhesion; (99) 293
 Bacterial uptake; (92) 237
 Barbiturate; (91) 15
 Basic compound; (99) 67
 Basic mixture; (97) 15

- Batch variability; (100) 207
 BATH; (99) 93
 Beagle; (99) 311
 Bendrofluzide; (94) 231
 Benfluorex; (91) 151
 Benzalkonium chloride; (93) 239
 Benzimidazole; (98) 1
 1-Benzotriazolylcarbonyl group; (99) 135
 Benzoxazole; (98) 1
 Benzylpenicillin; (98) 83
 Betamethasone; (96) 105
 Betamethasone 17-valerate; (96) 105
 Bevantolol; (99) 303
 Binary system; (93) 215
 Binding agent; (99) 37
 Bioadhesion; (94) 195
 Bioadhesive hydrogel; (100) 25
 Bioavailability; (92) 243; (94) 69
 Bioavailability decrease; (100) 249
 Biodegradable coating; (97) 133
 Biodegradable polymer; (93) R1; (94) 143; (97) 111; (98) 157
 Biological system; (92) 1
 Biorheology; (94) 195
 Biphasic affinity; (100) 233
 β -Blocker; (93) 49
 Bootstrap; (97) 141
 Brittleness index; (91) 173
 Bromhexine hydrochloride; (100) 227
 Brompheniramine; (91) 75
 Bronchoalveolar lavage; (97) 171
 Bropiramine; (96) 5
 Brush border membrane enzyme; (95) 171
 Buffering; (97) 219

 C; (93) 139
 Cabosil; (96) R7
 Caco-2; (99) 209
 Caco-2 cell; (95) 209
 Caffeine; (95) 93; (100) 41
 Calcergy; (98) 165
 Calcium-induced gelation; (97) 183
 Calorimetry; (99) 285
Candida albicans; (93) 201
 Canonical analysis; (97) 15
 Capsule; (98) 29; (98) 219
 Capsule dissolution; (96) 231
 Capsules; (94) 231
 Capture volume; (96) 51
 Carbamate; (91) 39
 Carbamazepine; (93) 7
 Carbomer; (100) 207
 Carbopol; (100) 25; (100) 65
 Carboxyfluorescein; (95) 51
 Carteolol hydrochloride; (95) 117
 Cascade impactor; (91) 111
 Casein; (92) 97
 Cationic excipient; (93) 233

 CD; (96) 91
 Cefalexin; (100) 213
 Ceftriaxone; (92) 47
 Ceftriaxone stability; (92) 47
 Cell culture; (99) 59; (99) 67; (99) 209
 Cellophane membrane; (92) 23
 Cell permeability; (92) 237
 Cellulose; (100) 49
 Cellulose derivative; (100) 33
 Cellulose polymer; (95) 57
 Cellulose powder; (97) 15
 Central composite design; (94) 49
 Central IV additive service; (97) 219
 Cephalixin; (98) 83
 Chemical stability; (100) 181
 Chemiluminescence; (99) 1
 Chemisorbate; (99) 21
 Chewable tablet; (96) 183
 Chiral drug; (92) 1
 Chirality; (94) 171
 Chitosan; (92) 211; (93) 233; (96) 33; (96) 139; (98) 181; (99) 13; (100) 257
 Chitosan malate; (98) 181
 Chitosonium malate; (100) 257
 Chloroquine diphosphate; (92) 183
 Chloroquine phosphate; (98) 181
 Chlorphenesin carbamate; (100) 133
 Chlorpheniramine; (91) 75
 Cholecystokinin B antagonist; (92) 63
 Cholesterol synthesis; (96) 1
 Cholesteryl acetate; (94) 89
 Chromameter; (94) 211
 Cigarette smoking; (100) 253
 Ciliotoxicity; (95) 101
 Ciprofloxacin; (95) 51
 Cisplatin; (99) 343
 Clopamide; (99) 327
 Cluster; (96) 175
 Coadministration; (93) 7
 Coalescence; (93) 61
 Coating; (91) 151; (94) 125
 Coenhancer; (91) 9
 Coenzyme Q₁₀; (93) 189
 Collagen; (91) 209
 Colloidal carrier; (94) 115
 Colloidal drug carrier; (96) R1
 Colon; (94) 125; (97) 1
 Colonic delivery; (91) 241; (95) 193
 Colon-specific drug delivery; (92) 105
 Colon targeting; (97) 133
 Coloring matter; (96) 139
 Commercial formulation; (100) 227
 Compaction; (95) 29; (95) 201; (97) 29; (97) 195; (99) 239
 Compaction behavior; (92) 123
 Compact strength; (93) 249
 Compensation analysis; (92) 211
 Complexation; (94) 69; (96) 5

- Complex formation; (96) 139; (99) 119
 Complex stability constant; (93) 201
 Compressed tablet; (93) 111
 Compression behavior; (94) 181
 Compression coating; (92) 35
 Compressive strength; (93) 249
 Computer software; (98) 209
 Concentration; (100) 189
 Concentration effect; (96) 111
 Conductivity; (96) 51
 Conglomerate; (99) 303
 Conjugate; (95) 85; (98) 121
 Consolidation; (95) 201; (97) 29; (97) 195
 Constant release; (91) 151
 Constant release rate; (94) 15
 Contact angle; (94) 223; (97) 101; (99) 239
 Continuous granulation; (96) 197
 Contour plot; (95) 57
 Control factor; (92) 115
 Controlled delivery; (93) R1; (95) 1
 Controlled drug delivery; (98) 157
 Controlled drug delivery system; (92) 225
 Controlled release; (91) 95; (92) 177; (94) 103; (95) 117; (96) 175; (98) 235; (99) 263; (100) 263
 Controlled release formulation; (97) 61
 Convective-diffusion; (96) 167
 Conventional tablet; (96) 183
 Coordination compound; (99) 119
 Copolymer; (100) 9
 Copper, interaction; (99) 119
 Coprecipitate; (93) 209
 Corneal clearance; (95) 229
 Corneal penetration; (93) 49
 Corticosteroid; (94) 211; (96) 105
 Cosolvent; (95) 23
 Cosurfactant; (93) 161
⁵¹Cr; (91) 75
 Creep; (91) 59
 Creep compliance; (92) 123
 Critical stress intensity factor; (91) 173; (99) 157
 Crosslinked poly(ethylene oxide); (94) 103
 Crosslinker effect; (92) 225
 Crosslinking; (96) 33; (100) 65
 Crystal analysis; (99) 125
 Crystal growth; (98) 189
 Crystal habit; (95) 143
 Crystallinity; (91) 123; (91) 133
 Crystallization; (93) 153; (94) 171; (99) 99
 Cubic phase; (98) 173
 Curcumin; (100) 93
 Cyclization; (91) 39
 Cyclodextrin; (98) 225; (99) 51
 α -Cyclodextrin; (96) 91
 β -Cyclodextrin; (94) 69; (96) 5; (96) 91; (100) 25
 γ -Cyclodextrin; (96) 91
 Cyclosporin A; (92) 197; (92) 203; (97) 205; (99) 263
 Cylindrical matrix; (100) 107; (100) 115
 Decomposition; (93) 153
 Deformation; (92) 137
 Deformation properties; (92) 55
 Degradation; (92) 233
 Degradation kinetics; (96) 243; (99) 73; (100) 181
 Degradation mechanism; (99) 73
 Degradation product; (96) 243; (97) 55; (99) 333
 Density; (100) 81
 Deoxyaciclovir; (99) 79
 2-Deoxy-4-pentulose; (93) 75
 Deposition pattern; (91) 111
 Dequalinium chloride; (92) 151
 Derivative spectrophotometry; (99) 333; (99) 351
 Derivative UV spectrophotometry; (93) 245
 Dermis effect; (100) 1
 Destabilizing effect; (97) 161
 Determination: Derivative spectrophotometry; (99) 327
 Dexamethasone; (92) 105
 Dextran; (92) 105; (100) 199
 Dialkylmethylidenemalonate; (92) 71
 Dialysis test; (93) 61
 Diclofenac; (92) 211
 Dideoxyinosine triphosphate; (98) 149
 Dideoxynucleoside; (95) 1
 Die design; (99) 7
 Dielectric; (96) 147
 Dielectric constant; (99) 29
 Difference spectrophotometry; (100) 227
 Diffusion; (92) 23; (92) 35; (96) 189
 Diffusion coefficient; (100) 155
 Diffusion kinetics; (95) 117
 Diffusion prediction; (94) 81
 α -(2,4-Difluorophenyl)- α -(1-(2-(2-pyridyl)phenylethenyl))-1H-1,2,4-triazole-1-ethanol bismesylate; (94) 11
 Dihydrate; (91) 195
 Diltiazem; (95) 161
 Dimensionality; (98) 57
 Dimethyl- β -cyclodextrin; (96) 91
 Dimethyl- β -Cyclodextrin; (99) 85
p-*N,N*-Dimethylphenylenediamine dihydrochloride; (93) 13
 Dipalmitoylphosphatidylcholine; (96) 157
 Diphenhydramine HCl; (94) 39
 Diphenylhexatriene; (98) 203
 Direct compression; (95) 201; (97) 15; (99) 99
 Direct compression tablets; (91) 143
 Direct tableting; (91) 183
 Disintegrant; (91) 217
 Disintegration; (98) 219
 Disruption index; (94) 171
 Dissociation constants; (92) 15
 Dissolution; (91) 217; (92) 211; (93) 111; (95) 143; (96) 5; (96) 119; (96) 167; (97) 119; (100) 25; (100) 65
 Dissolution behavior; (96) 91
 Dissolution enhancement; (93) 215
 Dissolution, in vitro; (95) 67
 Dissolution mechanism; (92) 97
 Dissolution model; (92) 115

- Dissolution probability; (92) 115
 Dissolution profile; (93) 215; (100) 33
 Dissolution rate; (91) 143; (100) 175
 Dissolution rate enhancer; (91) 23; (93) 209
 Dodecyl *N,N*-dimethylamino acetate; (92) 89
 Dodecyl *N,N*-dimethylamino isopropionate; (92) 89
 Dodecyltrimethylammonium bromide; (94) 31
 Dog; (94) 235
L-Dopa ester; (99) 135
 Dosage form; (99) 333
 Dose dependence; (97) 213
 Double-layer membrane; (98) 37
 Doxorubicin; (96) 157
 Doxycycline; (96) 13
 DPPG; (100) 41
 Drug; (91) 173
 Drug absorption; (97) 61; (99) 209
 Drug analysis; (99) 351
 Drug carrier; (100) 49
 Drug delivery; (91) 235; (93) 49; (93) 91; (94) 125; (96) 189; (100) 199; (100) 263
 Drug delivery system; (91) 209; (95) 1; (95) 153; (99) 173
 Drug deposition; (96) 111
 Drug-excipient interaction; (96) 231
 Drug leakage; (99) 145
 Drug preparation; (98) 239
 Drug redistribution; (91) 227
 Drug regeneration rate; (98) 121
 Drug release; (92) 35; (92) 55; (94) 39; (94) 115; (94) 153; (95) 77; (95) 135; (99) 13; (99) 247; (99) R5; (100) 115
 Drug release characteristics; (94) 75
 Drug release delay; (99) 21
 Drug release rate; (98) 181
 Drug solubility; (100) 107; (100) 115; (100) 257
 Drug solubilization; (98) 239
 Drug stability; (92) 191
 Drug targeting; (96) 23; (99) 275
 Dry granulation; (97) 29
 Dry powder inhaler; (91) 111
 DSC; (91) 1; (93) 27; (93) 153; (94) 89; (95) 43; (95) 117; (99) 219; (99) 303; (100) 143
 DSC screening; (97) 161
 DTPA; (100) 199
 Dyphylline; (91) 167

Echinococcus multicularis; (100) 271
E. coli; (99) 93
 Effective particle density; (99) 197
 Effervescent preparation; (96) 183
 Egg lecithin; (93) 161
 Elastic recovery; (95) 29
 Electrical conductivity; (94) 189
 Electrically modulated drug delivery system; (92) 225
 Electrical resistance; (98) 141
 Electrolyte; (100) 189
 Electro-osmosis; (92) 23
 Electrophoresis; (92) 225
 Electrophoretic mobility; (93) 221
 Elimination; (97) 1
 Elongation; (96) 217
 Emulsification method; (95) 77
 Emulsion; (91) 59; (94) 89; (96) 147
 Enalapril maleate; (93) 245
 Enantiomer; (92) 1
 Enantiomeric impurity; (94) 171
 Enantiomeric inversion; (92) 1
 Enantiomer resolution; (92) 1
 Encapsulation; (96) 67
 Enhancer; (91) 9
 Enhancer evaluation; (100) 41
 Enrofloxacin; (95) 51
 Enthalpy; (94) 135
 Enthalpy of fusion; (94) 171
 Enthalpy of immersion; (91) 123; (91) 133
 Entropy; (94) 135
 Entropy of fusion; (94) 171
 Enzymatic degradation; (99) 165
 Enzymatic hydrolysis; (100) 99
 EO9; (100) 181
 (–)-Ephedrinium 2-naphthalenesulfonate; (94) 171
 EPR; (99) 13
 EPR tomography; (98) 131
 Equilibrium humidity; (91) 123; (91) 133
 Erodible matrix; (91) 151
 Erosion; (94) 15
 Erythema; (93) 1
 Erythrocyte; (94) 161
Escherichia coli; (99) 293
 Ester prodrug; (100) 99
 Ethanol; (91) 9; (95) 161; (97) 39
 Ethanol injection; (95) 51
 Ethyl acetate; (97) 39
 Ethylcellulose; (91) 167
 Ethyl cellulose; (92) 29
 Ethylcellulose microcapsule; (92) 55
 Ethyl(hydroxyethyl)cellulose; (95) 219
 Eudispert; (95) 105
 Eudragit NE 30 D; (99) 181
 Eudragit RS; (98) 63; (98) 75
 Eudragit S; (91) 241
 Eudragit S[®] pH; (95) 193
 Excipient; (91) 173; (92) 197; (92) 203
 Excipient compatibility; (97) 161
 Excised human skin; (96) 79
 Extended drug release; (94) 15
 Extended release; (97) 183
 Extragranular incorporation; (97) 119
 Extrudate; (96) 197
 Extrudate diameter; (97) 79
 Extruded vesicle; (96) 67
 Extrusion; (95) 135; (99) 7; (100) 71
 Extrusion force; (99) 7
 Extrusion/spheronisation; (92) 211; (96) 197; (96) 21

- Extrusion/spheronization; (96) 119
 Extrusion-spheronization; (99) 197
 Eye; (93) 49
 Eye drops; (93) 239
- F_0 ; (92) 233
 Factorial design; (97) 149; (97) 183
 Factorial experimental design; (97) 161
 Fatty acid; (99) 109
 Fc-receptor targeting; (98) 149
 Fenoprofen acid; (96) 79
 Fibrin sheet; (91) 235
 Fick's law; (99) 181
 Film coating; (96) 129
 Film thickness variation; (93) 101
 Finite-dose acyclovir; (93) 139
 First-pass metabolism; (91) 39
 Fluidization pattern; (93) 101
 Fluidized bed coating; (93) 101
 Flumazenil; (98) 51
 Fluorescein isothiocyanate-dextran; (93) 91
 Fluorescence; (93) 121
 Fluorescence anisotropy; (98) 203
 Fluoroquinolone; (93) 121; (93) 131
 5-Fluorouracil; (92) 89; (94) 189; (99) 145
 Formation percentage; (93) 61
 Formulation; (92) 219; (93) 221
 Formulation effect; (99) 125
 Fourier transform infrared spectroscopy; (91) 51
 Fractional polarity; (99) 157
 Fracture; (91) 173
 Fragmentation; (97) 195
 Friction; (92) 157
 Froude-number; (92) 143
 Frusemide determination; (99) 333
- Gamma camera; (96) 183
 Gamma irradiation; (99) 37
 Gamma scintigraphy; (92) 167; (94) 235; (95) 111; (95) 193; (95) 229; (97) 47; (97) 61; (98) 63; (100) 81
 Gas bubbles; (100) 263
 Gas chromatography; (99) 351
 Gastric emptying; (92) 167
 Gastric retention; (94) 235
 Gastrointestinal stability; (96) 243
 Gastrointestinal transit; (94) 235; (96) 183; (97) 61; (100) 81
 Gastrokinetics; (93) 7
 Gel; (98) 37; (100) 143; (100) 155
 Gelatin; (95) 85
 Gelation mechanism; (99) 13
 Gel formulation; (93) 233; (99) 13
 Gelita Collagel; (99) 321
 Gellan gum; (95) 229
 Gel layer formation; (100) 165
 Gelling polymer; (94) 15
 Gibbs free energy; (94) 135
 Glaucoma; (93) 49
 Glucocorticoid; (92) 105
 Glucose; (96) R7
 Glycofurol 75; (95) 209
 Glycolic acid; (100) 9
 GPC; (100) 55
 Gral; (92) 143
 Granulation; (100) 241
 Granulation liquid; (95) 135
 Granule; (96) 197
 Granulometry; (95) 201
 Graphical method; (92) 15
 Gravity feed extruder; (95) 135; (99) 7
 Grinding; (95) 93
 Griseofulvin; (93) 215; (94) 31
 Guanine derivative; (99) 79
- Hairless mouse; (91) 85; (98) 131
 Hairless mouse model; (93) 139
 Hairless mouse skin; (98) 93
 HDL receptor; (96) 1
 Heat of immersion; (91) 247
 Heckel equation; (94) 181; (95) 29
 Heckel plot; (92) 123
 Hemicellulose; (91) 123; (91) 133
 Herpes simplex virus type 1; (93) 139
 Hexagonal phase; (98) 173
 Hexamethylmelamine; (95) 143
 Heywood shape coefficient; (99) 197
 HGM-CSF; (97) 213
 High-molecular weight polyoxyethylene; (93) 21
 High-pressure homogenizer; (91) 69
 High shear degradation; (95) 23
 High shear mixer; (92) 143
 High viscosity hydroxypropylmethylcellulose; (91) 167
 Hildebrand solubility parameter; (93) 183
 Histopathology; (95) 181
 HLB; (95) 77
 L-HPC; (96) 119
 HPLC; (93) 245; (94) 231; (97) 55; (98) 51; (98) 231
 HPLC-UV; (99) 85
 HPMC; (98) 57; (99) 37
 HT29-H; (99) 209
 Human; (94) 235
 Human enterocyte; (96) 1
 Human granulocytes; (99) 1
 Human immunodeficiency virus (HIV); (95) 1
 Human keratinocyte; (99) 67
 Human serum albumin; (96) 85
 Human skin; (92) 219; (94) 189; (98) 141; (100) 99
 Hyaluronate; (100) 199
 Hydrochlorothiazide; (93) 111; (93) 245; (100) 207
 Hydrocolloid dressing; (91) 51
 Hydrocolloid formulation; (99) 13
 Hydrocortisone; (95) 161
 Hydrocortisone acetate; (91) 85
 Hydrocortisone butyrate; (96) 91
 Hydrogel; (94) 103; (99) R5; (100) 65

- Hydrogen bonding parameter; (94) 153
 Hydrolysis; (93) 75; (95) 181; (99) 85; (99) 189
 Hydrophilic/lipophilic balance; (99) 29
 Hydrophilic matrix; (94) 15; (100) 207; (100) 263
 Hydrophobic network; (99) 125
p-Hydroxybenzoic acid ester; (93) 201
p-Hydroxybenzoic acid methyl ester; (99) 21
 Hydroxyethylcellulose; (95) 229
 Hydroxyl radical; (92) 151
 Hydroxypropyl- β -cyclodextrin; (91) 15; (93) 201
 Hydroxypropyl- β -Cyclodextrin; (99) 85
 Hydroxypropylcyclodextrin; (98) 239
 Hydroxypropylcyclodextrin complex; (98) 239
 Hydroxypropylmethylcellulose; (100) 143; (100) 155; (100) 165;
 (100) 175; (100) 241; (100) 263
 Hygroscopicity; (91) 195
 Hyperbolic relationship; (92) 137
 Hypoglycemic effect; (91) 29
- IBCA; (100) 55
 Ibuprofen; (92) 29; (92) 97; (92) 151; (92) 219; (93) 111; (94)
 59; (99) 125
 Illuminance; (93) 85
 Image analysis; (96) 119; (96) 205
 IM9 lymphoblastoid cell; (98) 19
 Immunoliposome; (98) 9
 Immunosuppression; (97) 205
 Immunosuppressive agent; (99) 263
 Impulse; (95) 67
 Inclusion complex; (91) 15; (93) 201; (96) 91
 Indomethacin; (91) 75; (92) 55; (92) 191; (93) 21; (94) 115; (98)
 235; (100) 165
 Inert matrix; (96) 175
 Infrared thermoviewer; (92) 157
 Infusion; (97) 219; (98) 51
 Infusion container; (100) 189
 Injectable drug carrier; (94) 143
 In situ gelling vehicle; (95) 219
 Instrumental measurement; (94) 211
 Insulin; (91) 29; (95) 101; (95) 171
 Interaction; (93) 7; (93) 233; (98) 51; (98) 231; (100) 249
 Interfacial cross-linking; (96) 85
 Interleukin-2; (96) 41
 Intermolecular interaction; (99) 125
 Intestinal absorption; (99) 311
 Intestinal epithelium; (99) 209
 Intestinal microorganism; (99) 189
 Intestinal microorganisms; (97) 1
 Intestinal perfusion; (91) 105; (98) 165
 Intragranular incorporation; (97) 119
 Intramolecular rearrangement; (92) 63
 Intrinsic dissolution; (91) 195
 Intrinsic dissolution rate; (94) 171
 In vitro diffusion; (93) 21
 In vitro dissolution profile; (97) 93
 In vitro drug permeation; (96) 79
 In vitro drug release; (96) 79; (98) 219
 In vitro flux; (93) 139
 In vitro-in vivo correlation; (99) 67
 In vitro models; (100) 1
 In vitro percutaneous absorption; (98) 37
 In vitro permeation; (98) 93
 In vitro release; (95) 219
 In vivo absorption; (99) 51
 In vivo analysis; (100) 271
 In vivo antiviral efficacy; (93) 139
 In vivo disintegration; (95) 193
 In vivo study; (94) 69
 Ionic pathway; (99) 43
 Ionic strength; (92) 177; (99) 93
 Ionic strength effect; (97) 141
 Ionisation constant; (99) 79
 Ionization; (96) 13
 Ionization behavior; (94) 11
 Ion pair; (100) 219
 Iontophoresis; (92) 23; (96) 189; (98) 141
 Iron; (100) 93
 Irreversible thermodynamics; (97) 39
 Irritation; (95) 181
 Isolated film; (99) 181
 Isopropyl myristate solubility; (93) 27; (93) 37
 Isothermal stress testing; (97) 161
 Isotonicity; (100) 219
- K562 erythroleukemic cell; (98) 19
keto-enol tautomerism; (96) 13
 Ketoprofen; (99) 109
 Ketorolac tromethamine; (96) 231
 Kinetics; (92) 151; (96) 13; (98) 189; (99) 333
Klebsiella pneumoniae; (98) 1
- Label; (91) 111
 Labrafil; (96) 147; (100) 41
 Labrasol; (100) 41
 β -Lactam antibiotic; (99) 119
 Lactic acid; (100) 9
 Lactose; (92) 81; (95) 201; (96) 59; (97) 29; (97) 79; (97) 195
 Laminar flow; (96) 167
 Large unilamellar vesicle; (99) 145
 Latex; (96) 129
 Lauroylsarcosine; (93) 1
 Lauryl alcohol; (100) 9
Leishmania donovani; (96) 23
 Leukemia; (96) 67
 Levobunolol; (100) 219
 Liarazole; (99) 51
 Lignin; (91) 123; (91) 133
 Lipase-sensitive granule; (99) 337
 Lipid-collagen interaction; (91) 209
 Lipid dispersion; (93) 189
 Lipid fluidity; (95) 43
 Lipid mixing; (99) 219
 Lipid peroxidation; (91) 209; (100) 93
 Lipid vesicle; (99) 219
 Lipophilic dispersion; (99) 21

- Liposome; (91) 1; (91) 69; (95) 51; (95) 105; (96) 51; (96) 67; (96) 157; (97) 205; (98) 131; (98) 149; (98) 203
 Liposome-cell interaction; (98) 19
 Liposome stabilization; (91) 209
 Liquid chromatography; (96) 13; (100) 213
 Liquid crystal; (96) 79
 Liquid intrusion equipment; (92) 81
 Liquid intrusion method; (92) 81
 Local anesthesia; (98) 101
 Long-chain *cis*-unsaturated fatty acid; (98) 203
 Low density lipoprotein; (99) 275
 Low-pressure ultrafiltration; (94) 115
 Low-substituted hydroxypropylcellulose; (99) 229
 Low substituted *N*-octenylsuccinate starch; (91) 23
 Low-viscosity HPMC; (91) 151
 Lubricant; (91) 217; (96) 231
 Lubricant sensitivity; (97) 195
 Lumenal metabolism; (97) 1
 Luminal enzyme; (95) 171
 Lymph node targeting; (98) 9
 Lymphocyte; (98) 19

 Macrogol-trilaurin matrix; (99) 337
 Macromolecular carrier; (99) 135; (99) 285
 Macrophage activation; (96) R7
 Macroporous membrane; (92) 35
 Magnesium stearate; (96) 231; (97) 195
 Magnesium trisilicate; (100) 249
 Mannitol; (96) R7
 Manometry; (95) 67
 Marix tablet; (99) 229
 Matrix; (94) 59
 Matrix geometry; (100) 107; (100) 115
 Matrix tablet; (95) 67; (95) 117; (99) 247; (100) 143; (100) 155; (100) 165; (100) 175; (100) 257
 Mean dissolution time (MDT); (97) 93
 Mean residence time (MRT); (97) 93
 Mean yield pressure; (94) 181
 Mechanical properties; (92) 123; (96) 129
 Mechanical treatment; (95) 93
 Mechanism; (98) 189
 Medroxyprogesterone acetate; (98) 225
 Megestrol acetate; (98) 225
 Melting point; (94) 153
 Membrane; (91) 95
 Membrane-controlled system; (98) 113
 Membrane diffusion; (94) 81
 Membrane fluidity; (94) 161
 Membrane packing order; (94) 161
 Menatetrenone; (93) 85
 l-Menthol; (91) 9
 Metabolism; (97) 1; (98) 165
 Metabolite; (95) 127
 Metal-ion complexation; (93) 121; (93) 131
 Metered dose inhaler; (91) 111; (93) 221; (95) 111
 Methocel; (100) 143; (100) 155
 Method evaluation; (100) 213

 Methodology; (91) 235
 Methotrexate; (95) 85; (98) 9
 Methotrexate dialkyl ester; (100) 233
 Methotrexate monoalkyl ester; (100) 233
 Methylated β -Cyclodextrin; (99) 85
 Methylcellulose; (94) 39; (100) 143; (100) 155; (100) 165
 α -Methyldopa ester; (99) 135
 Methylpolymethacrylate; (94) 125
 Methylprednisolone; (92) 105
N-Methylpyrrolidone; (92) 243
 2-Methyltamoxifen derivative; (99) 59
 Metoclopramide; (100) 25; (100) 65
 Metoprolol tartrate; (91) 151
 Metronidazole; (92) 233; (98) 231
 MG2 Futura capsule filler; (91) 217
 Micelle; (92) 197; (92) 203
 Microcapsule; (96) 85
 Microcapsules; (92) 29
 Microcrystalline cellulose; (91) 123; (91) 133; (91) 143; (91) 183; (91) 247; (96) 59; (97) 79; (99) 157; (100) 49
 Microdialysis; (99) 135
 Microemulsion; (91) 157; (93) 161
 Microfine cellulose; (91) 183
 Microflora; (97) 1
 Microfluidization; (95) 23
 Microparticles; (97) 111
 Microporous membrane; (98) 113
 Microsphere; (91) 29; (94) 59; (94) 143; (95) 85; (98) 63; (98) 75; (98) 157; (99) 263; (100) 123
 Microspheres; (93) 153
 Miglyol[®] oil; (95) 161
 Minimal inhibition concentration; (93) 201
 Minoxidil; (96) 111
 Miotic response; (95) 229
 Mitomycin C; (98) 121
 Mixed micelles; (91) 105
 Mixed solvent system; (95) 57
 Mixture design; (91) 157
 Mixture experimental design; (100) 33
 Moisture absorption; (95) 57
 Moisture content; (96) 59; (96) 197; (97) 79; (97) 119
 Molecular modeling; (94) 81
 Molecular size; (100) 257
 Molecular weight; (94) 81
 Molecular weight dependence; (93) 91
 Morphine hydrochloride; (91) 9
 Morphology; (100) 55
 Mucoadhesion; (94) 195
 Mucoadhesive ointment; (95) 105
 Mucociliary transport; (95) 57
 Mucosal adhesion; (94) 195
 Mucus glycoprotein; (94) 195
 Mucus layer; (99) 209
 Multilamellar liposome; (98) 19
 Multilamellar vesicle; (99) 145
 Multiparticulate preparation; (97) 61
 Multi-particulate system; (93) 101

- Multiple unit; (91) 167
 Multiple unit system; (100) 49
 Multivariate analysis of variance; (91) 183
 Multivariate statistical analysis; (97) 15

 N₂-acetylacetylovir; (99) 79
 Nanocapsule; (100) 55
 Nanoparticle; (100) 55
 Nanoparticles; (92) 71
 Nanosphere; (99) 263
 Naproxen; (92) 29; (94) 23; (98) 37; (100) 99
 Nasal absorption; (93) 91
 Nasal formulation; (99) 165
 Nasal mucosa; (94) 161
 Nebuliser; (98) 45; (99) R1
 Nebulizer; (97) 205
 Neonatal tetanus; (93) R1
 Neutral compound; (96) 167
 Neutral large unilamellar vesicles; (98) 9
 Neutron activation; (98) 63
 Newborn infant skin; (98) 93
 Nicoumalone; (93) 13
 Nifedipine; (91) 23; (93) 209; (96) 33; (98) 157; (99) 337
 Nimustine; (99) 73
 Nitrendipine; (99) 351
 Nitrendipine photodegradation; (99) 351
 Nitrite; (92) 233
 Nitrofurantoin; (96) 243
 Nitrosourea; (99) 73
 NMR; (100) 55
¹³C-NMR; (96) 13
¹H-NMR; (96) 91
²H-NMR; (99) 219
 Nonane enhancer; (92) 243
 Nonionic surfactant; (92) 219; (100) 279
 Nonlinear regression; (92) 115
 Nonwoven membrane; (91) 95
n-Norgestrel; (97) 39
 Novel enhancer; (91) 85
 Numerical model; (96) 167
 Nylon; (99) 293

 Occlusion; (91) 51; (92) 243
 Octanoic acid; (100) 219
n-Octanol; (94) 135
 Ocular delivery; (93) 49
 Ocular irritation test; (100) 219
 Ophthalmic formulation; (95) 229
 Ophthalmic solution; (93) 21
 Optimization; (93) 183; (97) 149; (100) 71
 Oral administration; (91) 29; (94) 235; (95) 171; (99) 337
 Oral bioavailability; (98) 165
 Oral drug delivery system; (97) 183
 Oral mucosa; (95) 105
 Orientational factor; (95) 143
 OROS; (91) 75
 Orthogonal function; (92) 15
 Oscillation; (91) 59

 Osmolarity; (93) 61
 Osmotic behavior; (95) 43
 Osmotic pressure; (92) 177
 Overmixing; (91) 217
 o/w microemulsion; (100) 219
 Oxazepam, Polyoxyethylene glycol 6000; (99) 321
 Oxazolo(4,5-*b*)pyridine; (98) 1
 Oxodipine; (93) 215

 Packaging; (94) 223
 Parabolic permeability profile; (100) 233
 Paracetamol; (99) 99
 Parameter analysis; (96) 225
 Parenteral drug carrier system; (93) 189
 Parenteral fat emulsion; (99) 1
 Pareto analysis; (96) 225
 Partial-least squares; (91) 157
 Particle interaction; (91) 227
 Particle size; (91) 59; (91) 247; (95) 85; (96) 147; (99) 145; (100) 123; (100) 175
 Particle size effect; (97) 79
 Particle sphericity; (99) 197
 Partition coefficient; (93) 27; (93) 37; (93) 131; (95) 181; (100) 1; (100) 41
 Partitioning; (94) 135; (100) 219
 Passage time; (94) 49
 PEG 6000; (94) 69
 Pellet; (92) 167; (95) 29; (95) 135; (96) 119; (96) 197; (96) 205; (96) 217; (100) 71; (100) 81
 Pellet size; (100) 81
 Penetration enhancement; (99) 51
 Penetration enhancer; (92) 89; (94) 189; (95) 43; (99) 109; (99) 253
 Pentamidine isethionate; (98) 45; (99) R1
 Peptidase; (97) 171
 Peptide; (97) 171; (99) 165
 Peptide delivery system; (99) 263
 Percolation theory; (96) 175
 Percolation threshold; (96) 175
 Percutaneous absorption; (91) 85; (96) 105; (96) 249; (98) 101; (98) 113; (99) 51; (100) 41
 Percutaneous absorption, in vitro; (100) 99
 Percutaneous local anesthesia; (94) 75
 Perforated core; (91) 151
 Perforated matrix; (100) 107; (100) 115
 Permeability; (91) 167; (91) 209; (95) 181; (95) 209; (96) 33; (97) 133; (99) 181
 Permeability coefficient; (91) 157; (100) 1
 Permeametry surface area; (99) 197
 Permeation; (100) 219
 Permeation enhancer; (94) 161
 Peroral formulation; (92) 197
 Phagocytic uptake; (99) 1
 Pharmaceutical availability; (98) 29
 Pharmaceutical dosage form; (92) 167
 Pharmaceutical formulation; (97) 149
 Pharmaceutical technology; (97) 15
 Pharmacodynamics; (92) 1

- Pharmacokinetics; (92) 1; (93) 7; (95) 127; (97) 213; (98) 9; (98) 51; (99) 343; (100) 133; (100) 253
- Phase behavior; (93) 161; (95) 219
- Phase diagram; (98) 173; (99) 303
- Phase transition; (91) 1
- pH; (91) 241; (92) 177; (97) 141; (99) 93
- pH dependence; (98) 83
- pH-dependent polymer; (91) 241
- pH-dependent release; (91) 29
- pH-independent dissolution; (99) 337
- Phenobarbital; (98) 93
- Phenol; (91) 39
- Phenol red; (93) 91
- Phenothiazine; (94) 135
- Phenylalanine; (100) 271
- Phenylbutazone; (91) 1
- Phenyl butazone; (92) 151
- Phenylbutazone; (93) 111
- Phenylpropanolamine; (95) 67
- Phenytoin; (93) 7; (96) 139; (98) 189
- Phe-Phe-OMe; (100) 271
- Phonophoresis; (96) 249
- Phosphocitrate; (98) 165
- Phospholipid bilayer; (91) 1
- Photochemical stability; (100) 15
- Photodegradation; (92) 151
- Photon correlation spectroscopy; (93) 189
- Photon correlation viscosity; (95) 23
- Photoresponsive system; (99) R5
- Photostability; (93) 85
- Physical interaction; (91) 217
- Physical mixture; (98) 29
- Physical properties; (99) 37
- Pilocarpine nitrate; (95) 229
- Pindolol; (99) 303; (99) 327
- Placebo control: Aspirin; (91) 75
- P388 leukemia; (98) 121
- Pluronic[®] F-127; (100) 279
- Pneumocystis carinii* pneumonia; (98) 45; (99) R1
- Polarity; (94) 223
- Polarized light microscopy; (96) 79
- Poloxamer 407; (96) 41; (99) 1
- Poloxamer 407; (100) 279
- Polyacrylic acid; (94) 195
- Polyacryl starch microparticles; (96) 23
- Polyamino acid; (94) 143
- α,β -Polyasparthydrazide; (99) 285
- Polycarophil; (98) 235
- Poly(cyclohexylethylmethylidene malonate); (92) 71
- Poly(diallylmethylidene malonate); (92) 71
- Polydimethylsiloxane matrix; (94) 153
- Poly(DL-lactide-co-glycolide); (93) R1
- Poly(DL-lactide-co-glycolide); (98) 157; (99) 263
- Polyester; (99) 293
- Poly(ethylene glycol); (93) 215
- Polyethylene glycol; (94) 31
- Polyethylene glycol 6000; (96) 5
- PolyHEMA; (99) 293
- Poly(lactide-co-glycolide); (99) 247
- Poly(lactide-co-glycolide) powder; (99) 239
- Poly(L-lactide); (93) 153
- Polymer; (92) 225; (99) 37; (100) 123
- Polymer gel; (95) 153
- Polymer gel viscosity; (100) 207
- Polymer hydration; (100) 143
- Polymeric film; (96) 129
- Polymeric prodrug; (99) 135
- Polymerization; (100) 55
- Polymer matrix; (94) 103
- Polymer-micelle complex; (99) 285
- Polymer-micelle interaction; (99) 285
- Polymethylenemalonate ester; (92) 71
- Polymorphic behavior; (95) 93
- Polymorphic form; (95) 93
- Polymorphism; (91) 195; (92) 183; (95) 93
- α,β -Poly(*N*-hydroxyethyl)-DL-aspartamide; (99) 135
- Polyoxyethylene alkyl ether; (92) 219
- Polyoxyethylene dodecyl ether; (94) 31
- Polysaccharide; (96) R7
- Polysaccharide gel; (100) 199
- Polystyrene particles; (99) 1
- Polyvinylchloride; (100) 189
- Polyvinylidene chloride; (99) 293
- Polyvinylpyrrolidone; (99) 181
- Porosity; (95) 29; (96) 119
- Porous bead; (100) 49
- Porous silica release; (99) 21
- Portal blood; (98) 165
- Powder characterization; (93) 249
- Powder compaction; (92) 137
- Powder compression; (92) 157
- Powder contact angle; (92) 81
- Powder inhaler; (97) 47
- Powder mixing; (96) 231
- Powder mixture; (94) 181
- Power consumption; (95) 29
- Precipitation; (94) 89
- Prediction; (93) 85
- Prednimustine; (99) 275
- Prednisone; (91) 143
- Preformulation; (93) 85; (97) 161
- Press-coated tablet; (99) 173
- Pressurised MDI; (97) 47
- Presystemic de-conjugation; (99) 189
- Primaquine; (92) 71; (96) 23; (100) 15
- Procainamide hydrochloride; (93) 13
- Process variables; (91) 59
- Prodrug; (91) 39; (92) 105; (93) 27; (93) 37; (93) 49; (93) 177; (99) 189
- Progesterone; (94) 103
- Proguanil; (100) 249
- Prolonged release; (99) 229
- Propranolol; (92) 177; (99) 253; (99) 303
- Propranolol HCl; (92) 35; (100) 155

- Propranolol hydrochloride; (92) 243; (98) 235; (100) 165; (100) 175
 Protease; (97) 171
 Protein absorption; (95) 101
 Protein degradation; (95) 171
 Protein dissolution; (92) 97
 Protein stability; (96) 41
 Pseudoephedrine; (91) 75
 Pseudoracemate; (99) 303
 Pulmonary administration; (97) 171
 Pulmonary drug delivery; (95) 111
 Pulsatile release; (99) 173
 Pyridostigmine; (97) 55
 Pyridoxal hydrochloride; (97) 161
 Pyrrolidone derivative; (95) 43

 QSAR; (98) 1
 QSAR analysis; (93) 201
 Quality; (96) 225
 Quantitative analysis; (100) 213
 Quantitative structure-transportability relationship; (94) 81; (94) 153
 Quantum mechanics; (94) 81

 Rabbit; (98) 51; (99) 165; (99) 189
 Racemates; (92) 1
 Racemic compound; (99) 303
 Radiotelemetry; (92) 167
 Ranitidine; (100) 253
 Rat; (98) 113
 Rat skin; (99) 51
 Rat tracheal cilia; (95) 101
 Reaction; (97) 1
 Reaction order; (98) 209
 Regular solution; (94) 23
 Release; (95) 85
 Release dependence; (91) 235
 Release, in vivo; (95) 67
 Release kinetics; (99) 21
 Release mechanism; (91) 167; (98) 235; (100) 257
 Release model; (94) 103
 Release rate; (93) 153; (100) 155
 Repeated dosing; (95) 127
 Reservoir; (91) 95
 Reservoir device; (92) 177
 Residence time; (96) 59
 Respirable fraction; (100) 123
 Response surface design; (100) 71
 Response surface model building; (97) 149
 Retard formulation; (100) 33
 Retinoic acid; (98) 131
 Retinol; (91) 157
 Reversed-phase HPLC; (91) R1; (93) 183; (93) 239
 Reversibility; (99) 253
 Rheological properties; (91) 59; (91) 123; (91) 133
 Rheology; (95) 201; (99) 37
 Rotational motion; (99) 13
 Roundness; (96) 217

 Routine analysis; (93) 13
 Ruminant; (91) 95

 Salbutamol; (91) 111
 Salbutamol sulfate; (100) 227
 Salicylic acid; (97) 101
 Salicylic acid-arginine conjugate; (99) 189
 Saline; (97) 219
 Salt-base equilibrium; (98) 101
 Samarium oxide; (98) 63; (98) 75
 Sampling; (98) 209
 Screw speed; (94) 49
 Segregation; (93) 101
 Segregation coefficient; (94) 171
 Selective coating; (100) 107; (100) 115
 Selective drug delivery; (97) 133
 Self-association; (94) 11
 Self-emulsifying system; (96) 147
 Serial barrier; (91) 235
 Serum-free medium; (99) 59
 Shape; (96) 217
 Shape distribution; (96) 217
 Shape parameter; (96) 217
 Shed snake skin; (92) 89
 Silicone; (92) 177
 Simplex lattice design; (93) 183; (97) 149
 Simulation; (98) 209; (100) 33
 Simultaneous determination; (93) 239; (100) 227
 Simultaneous drug determination; (93) 245
 Single dosing; (95) 127
 Single step granulation/extrusion; (94) 49
 Site-targeted delivery; (95) 1
 Size; (96) 205
 Size distribution; (95) 77; (96) 205
 Size parameter; (96) 205
 Skin; (95) 181; (96) 111; (98) 131; (99) 253
 Skin blanching; (94) 211
 Skin hydration; (91) 51
 Skin irritancy; (92) 243
 Skin irritation; (93) 1; (99) 67; (99) 253
 Skin irritation/damage; (93) 139
 Skin lipid; (98) 173
 Skin penetration; (99) 109
 Skin penetration enhancer; (97) 39
 Skin penetration, in vitro; (92) 219
 Skin permeability; (99) 43
 Skin permeation; (91) 9
 Skin permeation enhancer; (95) 161
 Skin retention; (91) 85
 Slugging; (97) 29
 Small-angle X-ray diffraction; (96) 79
 Small angle X-ray scattering; (94) 89
 Sodium cholate; (95) 101
 Sodium dodecyl sulfate; (94) 31; (99) 285
 Sodium glycocholate; (95) 209
 Sodium lauryl sulfate; (91) 105
 Sodium salicylate; (98) 181
 Sodium taurocholate; (91) 105

- Sodium thiosulfate; (99) 343
 Solid dispersion; (94) 69; (96) 5; (98) 29; (98) 219; (99) 321
 Solid dosage form; (91) 23
 Solid lipid nanoparticles; (93) 189
 Solid solution; (94) 31
 Solid-state NMR; (94) 31
 Solid-state transformation; (91) 195
 Solubility; (94) 11; (94) 23; (94) 75; (94) 81; (95) 181; (97) 119; (98) 219; (98) 225
 Solubility analysis; (96) 91
 Solubility isotherm; (93) 201
 Solubility parameter; (99) 157
 Solubility parameters; (93) 27
 Solubilization; (92) 191
 Solute uptake; (100) 189
 Solution; (100) 219
 Solution viscosity; (97) 133
 Solvent classification; (93) 183
 Solvent drag; (97) 39
 Solvent effect; (91) R1
 Solvent evaporation; (98) 75; (98) 157
 Sorption number; (100) 189
 Soybean lecithin; (93) 161
 Spectrophotometry; (92) 15; (93) 13
 Spherical granule; (99) 197
 Spherical matrix; (100) 49
 Sphericity; (96) 217
 Spheronisation; (95) 135; (96) 225; (97) 79; (99) 7
 Spheronization; (96) 59; (100) 71
 Spheronization speed; (96) 59
 Spin labeling; (98) 131
 Splenomegaly; (100) 279
 Spontaneous emulsification; (100) 55
 Spray drying; (99) 239
 Spray mode; (93) 101
 Squalene; (93) 1
 S-shaped dissolution; (92) 115
 Stability; (91) 59; (92) 47; (92) 63; (93) 21; (93) 61; (93) 153; (93) 177; (93) 233; (96) 147; (97) 55; (97) 219; (98) 149; (98) 225; (99) 85; (100) 233
 Stability constant; (96) 91
 Stability testing; (98) 209
 Stabilizing effect; (97) 161
 Stable plurilamellar vesicle; (99) 145
 Stannous octoate; (100) 9
 Steady state mass; (94) 49
 Stereoselective HPLC; (94) 171
 Steric stabilization; (93) 221
 Sterilization; (92) 233
 Storage stability; (99) 145
 Stratum corneum; (98) 203
 Stratum corneum lipid; (99) 219
 Stratum corneum lipid liposome; (95) 43
 Stress relaxation; (92) 137
 Structural effects; (93) 121; (93) 131
 Structural elucidation; (96) 243
 Structure; (94) 31
 Subinhibitory concentration; (92) 237
 Submicron emulsion; (96) R1
 Submicron particles; (94) 89
 Substituted pyridine; (94) 153
 Substitution type; (100) 143
N-Succinyl-chitosan; (98) 121
 Sucralfate; (96) 183
 Sucralfate-NSAID association; (99) 173
 Sucrose; (100) 65
 Sucrose ester; (93) 209
 Sucrose laurate; (92) 197; (92) 203
 Sufentanil; (96) 189
 Sulfamethazine; (91) 95
 Sulfapyridine; (98) 75
 Sulfasalazine; (98) 63
 Supercritical fluid extraction; (97) 111
 Supercritical gas; (97) 111
 Super disintegrant; (97) 119
 Surface-active agent; (99) 29
 Surface area; (91) 247
 Surface energy; (94) 223
 Surface free energy; (97) 101
 Surface tension; (96) 147
 Surfactant; (91) 105; (92) 197; (92) 203; (93) 61; (93) 221; (96) 231; (96) R7
 Suspension; (94) 89
 Sustained release; (92) 211; (94) 59; (95) 127; (96) 139; (98) 57; (98) 181; (99) 311; (100) 257
 Sustained-release formulation; (100) 133
 Swellable matrix; (91) 167; (100) 115
 Swellable polymer; (94) 15
 Swelling; (94) 39; (98) 57; (99) R5; (100) 25; (100) 65; (100) 143
 Swelling control; (100) 257
 Swelling force; (99) 229
 Swelling process; (100) 107
 Synchrotron radiation; (93) 189
 Synergism; (92) 237
 Systemic de-conjugation; (99) 189
 Systemic delivery; (95) 1
 T-47D cell; (99) 275
 Tablet; (92) 55; (92) 123; (92) 197; (94) 235; (97) 55; (97) 119; (98) 219; (99) 37; (99) 311
 Tablet adjuvant; (92) 55
 Tablet coating; (91) 241; (92) 35; (95) 193
 Tableting; (91) 217; (92) 29; (95) 93
 Tableting excipient; (94) 181
 Tablets; (93) 245; (94) 231
 Tablet stability; (91) 143
 Tablet surface area; (97) 29
 Tableting; (92) 157
 Tamoxifen; (99) 59
 Tape-stripped hairless mouse skin; (100) 233
 Targeted delivery; (94) 143
 Tazifylline; (95) 161
^{99m}Tc; (91) 111
^{99m}Tc labeling; (97) 47

- Temperature; (100) 9; (100) 189
 Temperature effect; (98) 239
 Temperature response; (95) 153
 Temperature rise; (92) 157
 Tensile strength; (91) 143; (93) 249; (95) 29
 Terbutaline sulfate; (97) 47
 Terephthaloyl chloride; (96) 85
 Ternary mixture; (91) 227
 Ternary system; (93) 215
 Terodiline; (98) 113
 Terpene; (94) 189
 Testosterone; (100) 41
 Tetanus toxoid; (93) R1
 Tetracycline; (98) 231
 Tetracycline HCl; (100) 155
 Tetracycline hydrochloride; (100) 165
 Tetrahydroaminoacridine; (95) 161
 Theophylline; (97) 61; (97) 101; (97) 183; (98) 51; (98) 181; (100) 33; (100) 207
 Theophylline tablets; (92) 115
 Therapeutic system; (96) 67
 Thermal degradation; (96) 243
 Thermal energy; (92) 157
 Thermal stability; (93) 27
 Thermodynamic parameters; (96) 91
 Thermodynamics; (92) 211
 Thermodynamic transfer parameters; (94) 135
 Thermography; (92) 157
 Thermogravimetry; (93) 27
 Thermomechanical analysis; (100) 143; (100) 165
 Thermometric titration; (94) 135
 Thioguanine; (95) 51
 Three-point single edge notched beam; (91) 173
 Thymopentin; (98) 19
 Thymoxamine; (99) 85
 Tilisolol; (93) 49
 Time; (100) 9
 Timolol; (99) 253
 Timolol maleate; (95) 219
 Tissue distribution; (94) 143; (97) 213; (99) 343
 Tolbutamide; (94) 69
 Topical formulation; (98) 101
 Topical preparation; (94) 23
 Total platinum; (99) 343
 Toxicity; (95) 209
 Tragacanth; (95) 23
 Transcutol; (92) 219; (100) 41
 Transdermal delivery; (93) 27; (98) 93
 Transdermal drug delivery; (98) 141
 Transdermal formulation; (92) 203
 Transdermal penetration; (92) 89; (98) 173; (99) 253
 Transdermal penetration enhancer; (93) 1
 Transdermal permeation; (96) 189
 Transepithelial transport; (98) 83
 Transmission electron microscopy; (94) 89; (96) 79
 Transparent oil-water gel; (92) 191
 Treatment schedule; (98) 121
 Triamcinolone acetonide; (95) 51; (95) 105
 Tricyclic antidepressant; (94) 135
 Trimethyl- β -Cyclodextrin; (99) 85
 Trinitrobenzenesulfonic acid; (96) 85
 Tropic acid; (93) 239
 Tween 20; (93) 215; (96) 147
 Twin-screw extruder; (94) 49
 Twin screw extruder; (99) 7
 Ulcerative inflammatory disease; (95) 105
 Ultrasonic nebulisation; (98) 45
 Ultrasound; (96) 249
 Upscaling; (92) 143
 Urea; (99) 109
 Urease; (96) 41
 Ussing chamber; (99) 165
 UV spectrophotometry; (96) 13
 UV spectroscopy; (96) 91
 Vaccine; (93) R1
 Vehicle deposition; (96) 111
 Vehicle ionic strength; (100) 189
 Verapamil; (92) 23
 Verapamil HCl; (91) 167
 Vigabatrin; (93) 7
 Viscoelastic behavior; (92) 137
 Viscoelasticity; (92) 123; (95) 57
 Viscosimetry; (99) 285; (100) 165
 Viscosity; (93) 21; (95) 23
 Visual assessment; (94) 211
 Vitamin A acid; (98) 131
 Vitamin E; (93) 1
 Washburn method; (97) 101
 Washburn technique; (92) 81
 Water content; (94) 49
 Water in flux; (93) 61
 Water insoluble drug; (94) 15
 Water/*n*-octanol; (94) 135
 Water repellent effect; (91) 217
 Water solubility; (93) 27; (93) 37
 Water stability; (93) 37
 Water uptake; (99) 239; (100) 175
 Water vapor permeation; (99) 181
 Wavelength dependency; (93) 85
 Wet granulation; (92) 143; (98) 181; (99) 229
 Wet strength; (96) 129
 Work of adhesion; (99) 293
 Work of compaction; (95) 29
 w/o/w emulsion; (93) 61
 Xanthan gum; (95) 229; (100) 263
 XD405; (94) 11
 X-ray diffraction; (93) 189; (95) 93
 X-ray powder diffraction; (91) 195; (94) 31
 Young's modulus; (99) 157
 Zero point of charge; (97) 141
 Zidovudine; (96) 249